OBJECTIVE: To evaluate the effect of golimumab on haemoglobin levels in patients with RA, PsA or AS. METHODS: Secondary analysis was performed on integrated data from five randomized controlled studies: three RA, one PsA and one AS (2303 patients total). Golimumab 50 or 100 mg was injected s.c. every 4 weeks with or without MTX. Control groups received placebo injections plus MTX or background therapy. Patients with haemoglobin levels below the age- and sex-specific normal ranges were considered to have anaemia. Ferritin levels were used to distinguish anaemia of mixed aetiology (≥ 15 and <60 ng/ml) and anaemia of inflammation (≥ 60 ng/ml). Changes from baseline to weeks 14 and 24 in haemoglobin level were compared between treatment groups using an analysis of variance on the van der Waerden normal scores. RESULTS: At baseline, 21% of RA patients, 9% of PsA patients and 15% of AS patients had anaemia. Of these, 24%, 57% and 25%, respectively, had anaemia of inflammation. The median increase from baseline to week 14 in the haemoglobin level of anaemic patients was 0.3 g/dl in the control group and 0.9 g/dl in the golimumab group (P < 0.001). Haemoglobin levels improved within the subgroups of patients with anaemia of mixed aetiology (control, 0.4 g/dl vs golimumab, 0.7 g/dl) (P = 0.305) and with anaemia of inflammation (0.2 vs 1.4 g/dl, respectively) (P < 0.001). CONCLUSION: Compared with the control group, patients receiving golimumab treatment had significantly improved haemoglobin levels, particularly among patients with anaemia of inflammation.
RCT Entities:
OBJECTIVE: To evaluate the effect of golimumab on haemoglobin levels in patients with RA, PsA or AS. METHODS: Secondary analysis was performed on integrated data from five randomized controlled studies: three RA, one PsA and one AS (2303 patients total). Golimumab 50 or 100 mg was injected s.c. every 4 weeks with or without MTX. Control groups received placebo injections plus MTX or background therapy. Patients with haemoglobin levels below the age- and sex-specific normal ranges were considered to have anaemia. Ferritin levels were used to distinguish anaemia of mixed aetiology (≥ 15 and <60 ng/ml) and anaemia of inflammation (≥ 60 ng/ml). Changes from baseline to weeks 14 and 24 in haemoglobin level were compared between treatment groups using an analysis of variance on the van der Waerden normal scores. RESULTS: At baseline, 21% of RApatients, 9% of PsA patients and 15% of AS patients had anaemia. Of these, 24%, 57% and 25%, respectively, had anaemia of inflammation. The median increase from baseline to week 14 in the haemoglobin level of anaemic patients was 0.3 g/dl in the control group and 0.9 g/dl in the golimumab group (P < 0.001). Haemoglobin levels improved within the subgroups of patients with anaemia of mixed aetiology (control, 0.4 g/dl vs golimumab, 0.7 g/dl) (P = 0.305) and with anaemia of inflammation (0.2 vs 1.4 g/dl, respectively) (P < 0.001). CONCLUSION: Compared with the control group, patients receiving golimumab treatment had significantly improved haemoglobin levels, particularly among patients with anaemia of inflammation.
Authors: Mittie K Doyle; Mahboob U Rahman; Chenglong Han; John Han; Jon Giles; Clifton O Bingham; Joan Bathon Journal: Semin Arthritis Rheum Date: 2008-09-27 Impact factor: 5.532
Authors: Elizabeta Nemeth; Seth Rivera; Victoria Gabayan; Charlotte Keller; Sarah Taudorf; Bente K Pedersen; Tomas Ganz Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: J Braun; J Brandt; J Listing; A Zink; R Alten; G Burmester; W Golder; E Gromnica-Ihle; H Kellner; M Schneider; H Sörensen; H Zeidler; J Reddig; J Sieper Journal: Arthritis Rheum Date: 2003-08
Authors: Mahboob U Rahman; Jacqui Buchanan; Mittie K Doyle; Elizabeth C Hsia; Timothy Gathany; Shreekant Parasuraman; Daniel Aletaha; Eric L Matteson; Philip G Conaghan; Edward Keystone; Désireé van der Heijde; Josef S Smolen Journal: Ann Rheum Dis Date: 2011-06-27 Impact factor: 19.103
Authors: Ioannis E Koutroubakis; Claudia Ramos-Rivers; Miguel Regueiro; Efstratios Koutroumpakis; Benjamin Click; Marc Schwartz; Jason Swoger; Leonard Baidoo; Jana G Hashash; Arthur Barrie; Michael A Dunn; David G Binion Journal: Inflamm Bowel Dis Date: 2015-07 Impact factor: 5.325
Authors: Iria V Seoane; Eva Tomero; Carmen Martínez; Rosario Garcia-Vicuña; Yasmina Juarranz; Amalia Lamana; Elena Ocón; Ana M Ortiz; Nieves Gómez-León; Isidoro González-Álvaro; Rosa P Gomariz Journal: J Mol Neurosci Date: 2015-02-25 Impact factor: 3.444
Authors: Stefan Schreiber; Philip Rosenstiel; Neha Mishra; Konrad Aden; Johanna I Blase; Nathan Baran; Dora Bordoni; Florian Tran; Claudio Conrad; Diana Avalos; Charlot Jaeckel; Michael Scherer; Signe B Sørensen; Silja H Overgaard; Berenice Schulte; Susanna Nikolaus; Guillaume Rey; Gilles Gasparoni; Paul A Lyons; Joachim L Schultze; Jörn Walter; Vibeke Andersen; Emmanouil T Dermitzakis Journal: Genome Med Date: 2022-09-24 Impact factor: 15.266
Authors: James W Swann; Lada A Koneva; Daniel Regan-Komito; Stephen N Sansom; Fiona Powrie; Thibault Griseri Journal: J Exp Med Date: 2020-09-07 Impact factor: 14.307